Idexx Laboratories (IDXX)
NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-08
$555.67-2.56%
Close 2026-07-08 · 1-day change
Reading IDXX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IDXX free→NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-08
Reading IDXX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IDXX free→QuarterlyIQ Insights · IDXX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces First Quarter Results,” issued by the Company on May 5, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIES,…
Executive Vice President, Global Strategy and Commercial — Nimrata Hunt, PhD: Dr. Nimrata Hunt is departing from her role with significant severance benefits.
Director — Ms. M. Anne Szostak: Ms. Szostak is retiring from the Board of Directors after her tenure since 2012.
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results,” issued by the Company on February 2, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly auth…
CEO — Jonathan (Jay) Mazelsky: Jonathan (Jay) Mazelsky is retiring and transitioning to the role of Executive Chair, while Michael (Mike) Erickson will become the new President and CEO.
Entry into a Material Definitive Agreement Amendment No. 2 to Fourth Amended and Restated Credit Agreement On November 12, 2025, IDEXX Laboratories, Inc. (the “ Company ”), with IDEXX Distribution, Inc., IDEXX Operations, Inc., OPTI Medical Systems, Inc., IDEXX Laboratories Canada Corporation, IDEXX B.V., IDEXX Laboratories B.V., IDEXX Laboratories GmbH, and IDEXX Holdings II GmbH, each a wholly-owned subsidiary (whether directly or indirectly held) of the Company (collectively, the “ Borrowe…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant To the extent required, the information set forth in
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces Third Quarter Results,” issued by the Company on November 3, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORA…
Director — Karen Peacock: Election of Karen Peacock as an independent Class I Director.
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces Second Quarter Results,” issued by the Company on August 4, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORAT…
Director — Joseph L. (Jay) Hooley: Election of a new independent Class III Director and appointment to committees.
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces First Quarter Results,” issued by the Company on May 1, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIE…
Director — Dr. Asha Collins: Dr. Asha Collins resigned from the Board of Directors without a named successor.
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results,” issued by the Company on February 3, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly auth…
The filing describes the adoption of a nonqualified deferred compensation plan for certain employees.
Other Events. On December 3, 2024, the Finance Committee of the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”) authorized an increase in the Company’s ongoing share repurchase program, authorizing the repurchase of up to five million additional shares of the Company’s common stock. Repurchases may be made at management’s discretion from time to time in the open market (including through Rule 10b5-1 plans) or in negotiated transactions. These shares are in additio…
Chief Financial Officer (CFO) — Brian P. McKeon: Brian P. McKeon is retiring as CFO, and Andrew Emerson has been appointed to succeed him.
Director — Jonathan W. Ayers: Mr. Ayers resigned from the Board and its finance committee.
Entry into a Material Definitive Agreement. Effective as of October 31, 2024, IDEXX Laboratories, Inc. and certain of its affiliates entered into: (i) an Amendment No. 9 (the “U.S. Amendment”) to the Agreement effective as of October 16, 2003 between IDEXX Operations, Inc. and Ortho-Clinical Diagnostics, Inc. (“Ortho”), as amended by Amendment Nos. 1 to 8 and the Letter Agreement dated July 28, 2023 (the “Original U.S. Supply Agreement” and as amended by the U.S. Amendment, the “U.S. Supply A…
Results of Operations and Financial Condition. On October 31, 2024, the Company filed the Original 8-K, which included the Original Earnings Release. This Amended 8-K replaces the Original Earnings Release with the amended earnings release, which is attached as Exhibit 99.1 to the Amended 8-K (the “Amended Earnings Release”). This Amended Earnings Release corrects and replaces the range of projected 2024 comparable operating profit margin expansion of 70 to 100 basis points set forth in the “…
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces Third Quarter Results,” issued by the Company on October 31, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORA…
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces Second Quarter Results,” issued by the Company on August 6, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORAT…
Executive Vice President — James F. Polewaczyk: Mr. Polewaczyk retired and entered into a consulting agreement with the company.
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces First Quarter Results,” issued by the Company on May 1, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIE…
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces Fourth Quarter and Full Year 2023 Results,” issued by the Company on February 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly auth…
Importance-ranked changes since the prior daily snapshot.
Valuation rose by 10.6 points (from 39.1 to 49.7).
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.